

Examine the Patient!

- General: ambulation, gait speed, dehydration, LE edema, weight loss, notate it!
- Outlet obstruction: high-grade prolapse,* prostate, impaction, rectal tone
- Skin: Chemical dermatitis, vaginal atrophy
- Behavioral assessment: Voluntary pelvic floor contraction
- Neurologic deficits: able to give their history,
 recall




* > Grade 2; To introitus or greater


Assessing The Elderly For Anesthesia

Cardiac Risk Assessment determines need for further assessment:

- Major/Current: severe arrhythmias or valvular disease, uncompensated heart failure, unstable angina
- Risk of MACE (major adverse cardiac events): ACS-NSQIP risk calculator https://riskcalculator.facs.org/RiskCalculator/
- Functional capacities: Duke Activity Status Index https://www.mdcalc.com/duke-activity-status-index-dasi







Common Geriatric Problems

- LUTS, especially bothersome is nocturia
- UTIs
- Sexual dysfunction
- Renal Transplantation: increasing ESRD
- Prostate Cancer: affecting screening/treatment Bladder Cancer
- "Incidentalomas" incl renal and adrenal masses, but also labs, PSA screening, cytologies



LUTS: Describe As Symptom, Not As An Etiology

Storage

- Daytime frequency
- Nocturia
- Urgency
- Incontinence

Voiding

- Hesitancy (not "prostatism" nor "BPH")
- Straining
- Stream slow, intermittent "
- Hesitancy
- Dribbling, esp. terminally "


In the elderly, the diff dx must include **UAB**, **nocturnal polyuria**, **loss of renal concentrating ability** near the top of the differential.



ARS Q1:

An elderly man with LUTS has a large prostate with this uroflowometry:

- a) Has BPH
- b) Has LUTS, NOS
- c) Has weak detrusor power
- d) Has BPH and weak detrusor.





Answer: B

- B. Has LUTS, NOS
- The uroflow is a screening study and does not make the diagnosis of either obstruction (from any source) nor a weak detrusor.
- This represents LUTS, but can not further be determined why...could be UAB or BOO or both.





AUR

- Painful, palpable or percussable, unable...
- Associated: anesthesia, pain, alcohol, travel, constipation, GU instrumentation, UTI, overdistension
- Studies: BUN/Cr, U/A. Don't get a PSA acutely; PFS to differentiate BOO from UAB
- Treatment:
 - Decompress and monitor (how long?): hematuria in 2-16%, post-relief of obstruction diuresis in 0.5% to 52% (usually AUR on CUR)
 - α-blocker in all men: TWOC successful in 60%*



Chronic Urinary Retention: Management and outcomes for non-neurogenic CUR longitudinally are poorly defined. Consensus definition as PVR > 300 for >6 months, documented on two or more occasions. Indications of high risk CUR Radiological findings: Hydronephrosis Hydroureter Laboratory findings: . Stage 3 chronic kidney disease (estimated glomerular filtration rate 30 to 59 mL/minute/1.73 m²) · Recurrent, symptomatic, culture proven UTI · Culture proven systemic urosepsis Assess risk and symptoms to determine recommended · Urinary incontinence associated with perineal skin changes treatment. · Urinary incontinence associated with sacral decubitus ulcers Treatment recommendations for CUR stratified by symptoms and risk High Risk Asymptomatic Do not treat 1. Drain bladder, reassess risk 2. Treat CUR if associated with risk Drain bladder, reassess risk Symptomatic Discuss symptom specific treatment 2. Treat CUR if associated with risk options 3. Discuss symptom specific treatment Stoffel J, Peterson AC. et al. AUA White Paper on Non-neurogenic Chronic Urinary retention: Consensus Definition Treatment Algorithm and Outcome End Points, J Urol. 198, 153-160, 2017





ARS Q2:

An elderly woman presents with chronic urinary retention; she *should* undergo a UDS to determine if this is secondary to outlet obstruction if:


- a) The post void residual is greater than 1 l
- b) She has had a prior outlet procedure, such as a sling
- c) She is less than 65 years old
- d) She is asymptomatic and this was an incidental finding



Answer: B

- B. She has had a prior outlet procedure, such as a sling.
- A prior outlet procedure is a common cause of outlet obstruction in women. None of the others mandate a UDS.






Urge, Urge Incontinence is a Symptom, Not a Diagnosis.

- Obstruction in women produces storage symptoms (urge, urge incontinence) more commonly than voiding symptoms.
- "Neurogenic bladder" occurs only in the setting of a defined neurologic disease that is associated with those LUTS symptoms, eg. spinal cord injury, multiple sclerosis, post- CVA, etc. Don't use NGB for urge, urge incontinence symptoms.
- Overactive Bladder is, by definition, idiopathic. And not neurogenic! Don't use OAB when you mean NGB if the patient has relapsing remitting MS with significant storage symptoms.





ARS Q3:

An elderly woman has urge and urge incontinence. The finding most consistent with the diagnosis of OAB is:

- a) She has hematuria
- b) She has Parkinsonism
- She is poorly ambulatory due to severe osteoarthritis and leaks on the way to the bathroom
- d) Her post void residual volume is 250 cc
- e) Her daughter is the only one complaining of the leakage, the patient is unconcerned



Answer: C

C: She is poorly ambulatory due to severe osteoarthritis and leaks on the way to the bathroom.

Bladder is firing before she can reach the toilet. Although a large mobility component is present, **this is OAB.** Management of the mobility component will be a major part of her treatment plan.

- The patient with hematuria may have these irritative symptoms due to a bladder cancer and requires a hematuria evaluation. **Not** OAB.
- The patient with a known neurologic disease that commonly produces storage symptoms has a neurogenic bladder. Not OAB.
- The patient with an elevated PVR may have UAB leading to overflow incontinence, a weak detrusor. Not OAB.
- OAB is a symptom- complex wherein symptoms are bothersome to the patient.



Impact of High Grade Incontinence

- Social withdrawal: affecting sense of hygiene, odor, especially when pads insufficient.
- Disturbed sleep.
- Fall risk.



 Always ask about coexisting fecal incontinence as patients will not volunteer this information.


With increasing longevity, there's a longer time to live with poor QOL.



Medications and the Elderly

The Beers Criteria for Potentially Inappropriate Medication (PIM) use in Older Adults AUA White Paper 2015

- Common meds included as PIMs are *long-term* nitrofurantoin, as well as α -1 blockers, antimuscarinics, sedatives...
- HEDIS® HRM list of these PIMs has been implemented as a negative quality indicator, though not originally intended as such.



Polypharmacy and the Elderly

- Average elderly patient is on 2-6 prescription meds and 1-3 OTCs.
- Anticholinergics, anesthetics, analgesics, sedatives, antidepressants, all neuroleptics are commonly associated with weakening detrusor function.
- Antihypertensives, diuretics, ACE inhibitors with increase in nocturia, urge, urge incontinence symptoms Hall SA, Chiu GR. Commonly Used
- Pharmacologic changes with Age:
 - − Decreased muscle mass, increased body fat \rightarrow decrease in total body water. [Lipid-soluble drugs] will \uparrow , [water-soluble drugs] will \downarrow .
 - Protein binding usually \downarrow , [barbiturates, benzodiazepines, opioids] \uparrow .
 - Decreased renal function will \downarrow clearance of most antibiotics, \underline{x} Fosamycin which can be used with Cr Cl of 20 ml/mg or higher.



Ex. Antimuscarinics & Impaired Cognition

- Commonly UI & dementia coexist.
- Dementia is underdx by non-geriatricians, esp. if mild!
- Antichol more likely to be used in dementia.+
 - Should not be used concomitantly with cholinesterase inhibitors (the dementia, Parkinson's drugs, sleep disorders)
- Avoid antimuscarinics b/c \(\gamma\) vulnerability to cognitive & functional AE.*

*Gormley AE, Lightner DJ, OAB, AUA Guideline 2012; Beers Criteria AGS, 2015

+Green AN, Use of Antimuscarinics, 2017



Are our elderly patients are missing out on the benefits of antimuscarinics? Consider, in those best of all possible worlds drug trials...

	Continence—attributable events per 1,000, n (range)	Continence—number needed to treat (NNT), n (range)	Clinically meaningful improvement—attributable events per 1,000, n (range)	Improvement NNT, n (range)	Discontinuation for adverse events compared to placebo (%)	Dry mouth compared to placebo (%)
Darifenacin	NA	NA	117 (57–177)	9 (6-18)	4.6/3.3	22/5.6
Fesoterodine	130 (58-202)	8 (5-17)	100 (56-145)	10 (7-18)	6.0/3.0	27/7.0
Oxybutynin	114 (64-163)	9 (6-16)	167 (95-240)	6 (4.0-11)	10/5.0	34/15
Propiverine	163 (86-239)	6 (4-12)	192 (132-252)	5 (4-8)	NA	NA
Solifenacin	107 (58-156)	9 (6-17)	180 (97-263)	6 (4-10)	5.0/4.0	21/5.0
Tolterodine	85 (40-129)	12 (8-25)	96 (42-149)	10 (7-24)	4.0/3.0	18.4/6.7
Trospium	114 (83-144)	9 (7-12)	NA	NA	5.8/3.9	15.1/4.5

The figures relate to available anticholinergic agents and head-to-head comparisons with placebo or other anticholinergics. Attributable events represent the difference between placebo response and active drug response.

Neurourology and Urodynamics DOI 10.1002/nau



11.71 11.65 480 473 Continued: What about Mirabegron in BPW trials? SCORPIO: Achieving Zero incontinence @12 wks: nence opisodes/24 h (FAS-1) and mean number of micturitions/24 h (FAS-5) SCORPIO. "Statistically significantly superior compared with placebo at the 0.05 level with multiplicity adjustment. ■, placebo; ■, mirabegron 50 mg; ■, totlerodine R4 mg. Mirabegron 50 mg 45.1% Tolterodine 4 mg 47.3% Placebo 40.5% mean change from baseline TAURUS: 1 yr, • Not designed to demonstrate Wirabegron 100 mg differences, efficacy "appears Tolterodine ER 4 mg maintained" A safety study

Pharmacotherapy Trials are "BPW" Results

"All is for the best in the best of all


- Motivation of the patient is high
- Intensive follow-ups are required
- Generally of moderate severity for entry
- Excluded comorbidities including diseases with failure to concentrate, cardiac and vascular disease, frailty, immobility, psychiatric disorders, polydipsia...

These trial results will not be achieved in our general urology patients! Let alone the geriatric ones!



Primary treatment of bothersome urge, urge incontinence, like OAB, is also behavioral.

- Education on normal physiology.
- Fluid intake, fruits, vegetables, fluid schedules.
- Restore/maintain general health, weight, and bowel function.
- Cognitive and mobility issues: Timed and prompted voiding.
- Pelvic floor muscle re-education: especially Quick Flicks for urge suppression +/- formal biofeedback.




Patient 1		Patient 2		
• 7:00am	200 cc	• 7:00am	650 cc	
• 8:15am	75 cc	• 8:15am	500 cc	
• 9:00am	100 cc	• 9:00am	375 cc	
• 12:30am	125 cc	• 12:30am	525 cc	
• 2:00pm	75 cc	• 2:00pm	475 cc	
• 3:15pm	75 cc	• 3:15pm	450 cc	
• 4:30pm	100 cc	• 4:30pm	325 cc	
• 8:00pm	125 cc	• 8:00pm	425 cc	
• 10:30pm	100 cc	• 10:30pm	500 cc	
• 3:00am	175 cc	• 3:00am	800 cc	

Setting Realistic Expectations

- Understanding Bladder Physiology and their bladder.
- Cure Rates with OAB, the easier one than poor cognition...
 - Studies report mean change, not generally cure.
 - These are generally intact and not declining adults.
 - Yet, in best practices, ex. TAURUS and SCORPIO trials, "% of responders incontinence at baseline and became dry post-baseline was numerically (although not statistically significantly) higher for mirabegron 50 and tolterodine than for placebo" (emphasis mine)
- Commitments over time, multiple modalities, costs.
- Demonstrable improvements for the patient: Use of validated Questionnaires and bladder diaries.

The elderly will be more challenged with any and all of these expectations placed upon them.





OAB and Non-Compliance with Pharmaceuticals

Drug Discontinuation: Response:

#1. Lack of efficacy

- a. Duration of use
- b. Switch (1° to reduce TEAEs)
- c. Start and/or continue behavioral tx! *
- 2. TEAEs

3. Cost

Use extended release, treat AE

Use inexpensive generics

* 13 clinical trials, 1.8K patients, pharmacotx better than retraining alone, but both better than pharmocotx alone. Alhasso et al, Cochrane ,2006



OAB and Cortical Function




- OAB is defined as idiopathic.
- Frontal micturition center which is normally suppressive is deactivated in OAB.
- Tolterodine-induced changes in NIRS-UDS improved prefrontal cortex activity and reduced bladder urge sensations. Sakakibara et al, NeuroUrol 2014
- NB- requires higher brain function to have socially acceptable bowel and bladder & get out of diapers.
- "Poor short-term memory? Don't expect continence."


 Surface Surface



Will You Recognize Normal Pressure Hydrocephalus?

- Potentially treatable cause of incontinence.
- Triad: Typical gait "magnetic feet", slowness of thought/actions, urinary incontinence
- If you suspect it, refer it!





ARS Q4:

Nocturnal Total Urine Volumes:

- a) Decrease with age
- b) Increase with age
- c) Are normally larger than diurnal volumes
- d) Are normally greater than 35% of total 24 h volume



Answer: B

- B. Increase with age
- Nighttime urine volumes increase with age, but are only rarer larger than diurnal volumes.
 Urine volumes at night >35% of total 24 h volumes defined nocturnal polyuria and is not normal.



Dysfunctional Voiding (DFV)

- Hallmark is urge, frequency; women > men, all ages.
- Both storage and voiding symptoms
 - Intermittency or fluctuating due to *non-neurologic* involuntary intermittent contractions of the pelvic floor. Can be highly obstructive.
 - Disturbance of coordination & induction of voiding by PMC, perhaps "abnormal guarding" (?)→sphincter and detrusor dysfunction.
 - In the elderly, can be 2⁰ to uninhibited detrusor contractions leading to sensation of urge.
 - Associated (not causal) increase in UTIs.



More Tidbits: Lichen Sclerosus:

No longer called BXO, nor LS et atrophicus.

- Chronic inflammatory dermatitis, unknown etiology, immune components likely.
- Can be obstructive. In both men and women.
- 3 to 10: 1 W:M.
- Two incidence peaks: premenstrual & elderly. Estimated to occur in 1 in 30 nursing home female residents.
- White, intensely pruritic papules coalescing into plaques→ adhesive and obliterative scarring.
- 5% with SCC, biopsy if ulcerated.
- 10 tx with clobetasol, gentle hygiene.





Lichen sclerosus demonstrating classic hourglass or figure 8 vulvar and perianal distribution. Courtesy of Wilford Hall Medical Center slide files, and emedicine. Medscape. Accessed 8-12-17.

AUA	AUA Guidelines Statement revision 2014					
Guidelines are the		Evidence Strength A (High Certainty) ²	Evidence Strength B (Moderate Certainty) ³	Evidence Strength C (Low Certainty) 4		
distillation of the best	Strong Recommendation ¹	Benefits>Risks/Burdens (or vice versa)		Benefits >Risks/Burdens (or vice versa)		
evidence and are a major		Net benefit (or net harm) is substantial				
emphasis in resident	Moderate Recommendation ¹	Benefits>Risks/Burdens (or vice versa)		Benefits>Risks/Burdens (or vice versa)		
education, board		Net benefit (or net harm) is moderate				
certification, recertification	Conditional Recommendation	Benefits=Risks/Burdens		Balance between Benefits & Risks/Burdens unclear		
and MOC.	(No apparent net benefit or harm)			uncieal		
A U A GUIDELINES		Best action depends on individual patient circumstances		Alternative strategies may be equally reasonable		
Marie	Statement stre	ngth is linked to the	e evidence strength	ı, i.e.		
	* * * * * * * * * * * * * * * * * * * *	st patients in most circumsta th is unlikely to change confic				
American Urological Association Education & Research	4. Better evidend	ce could change confidence. ce is likely to change confiden	nce.			